Full Text
Cost Per Responder Of Apremilast Versus Etanercept And Adalimumab In Patients With Active Psoriatic Arthritis

Abstract

Authors

T. Tencer Z. Clancy F. Zhang

Back to Volume 17, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×